newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 followed by KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on track to begin by year-end 2021 Enrollment continues at the highest dose level in Phase 1 I